SCHEMBL1506754

SCHEMBL1506754

C=Cc1ccccc1NCCCCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
CNR2 P34972 4/20 0.42
KCNH3 Q9ULD8 1/20 0.41
CNR1 P21554 1/20 0.39
TLR8 Q9NR97 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
CHRM2 P08172 1/20 0.38
S1PR2 O95136 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 3/20 0.37
HTT P42858 1/20 0.37
ALDH1A1 P00352 2/20 0.37
NPC1 O15118 1/20 0.37
STAT1 P42224 1/20 0.37
RAB9A P51151 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10628478 0.98 L3MBTL1 (0.45) L3MBTL1CNR2KCNH3CNR1TLR8
SCHEMBL23248725 0.98 L3MBTL1 (0.45) L3MBTL1CNR2KCNH3CNR1TLR8
SCHEMBL10623845 0.98 L3MBTL1 (0.45) L3MBTL1CNR2KCNH3CNR1TLR8
SCHEMBL27636013 0.98 L3MBTL1 (0.45) L3MBTL1CNR2KCNH3CNR1TLR8
SCHEMBL10628642 0.95 TLR8 (0.43) L3MBTL1CNR2TLR8CHRM2SMN1; SMN2
SCHEMBL10628437 0.87 IDO1 (0.43) TLR8MAPTHTTALDH1A1KDM4E
SCHEMBL11623780 0.84 L3MBTL1 (0.43) L3MBTL1CNR2KCNH3CNR1TLR8
SCHEMBL4954523 0.84 L3MBTL1 (0.43) L3MBTL1CNR2KCNH3CNR1TLR8
SCHEMBL4958966 0.84 L3MBTL1 (0.43) L3MBTL1CNR2KCNH3CNR1TLR8
SCHEMBL4958970 0.83 L3MBTL1 (0.43) L3MBTL1CNR2KCNH3CNR1TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2298820-B1 POROUS RESIN BEAD AND METHOD FOR PRODUCING NUCLEIC ACID USING THE SAME NITTO DENKO CORP (JP) 2020-11-04 EP disclosed
EP-2298821-B1 POROUS RESIN BEAD AND METHOD FOR PRODUCING NUCLEIC ACID USING THE SAME NITTO DENKO CORP (JP) 2020-07-29 EP disclosed
EP-2886564-B1 Porous resin bead and production method of nucleic acid by using same NITTO DENKO CORP (JP) 2016-09-21 EP disclosed
EP-2886564-A1 Porous resin bead and production method of nucleic acid by using same Nitto Denko Corporation (JP) 2015-06-24 EP disclosed
US-20150152234-A1 POROUS RESIN BEAD AND PRODUCTION METHOD OF NUCLEIC ACID BY USING SAME NITTO DENKO CORPORATION (JP) 2015-06-04 US disclosed
US-9045573-B2 Solid-phase support for oligonucleotide synthesis and oligonucleotide synthesis method NITTO DENKO CORPORATION (JP) 2015-06-02 US disclosed
US-8802745-B2 Porous resin bead and method for producing nucleic acid using the same NITTO DENKO CORPORATION (JP) 2014-08-12 US disclosed
US-8653152-B2 Porous resin bead and method for producing nucleic acid using the same NITTO DENKO CORPORATION (JP) 2014-02-18 US disclosed
US-20130317206-A1 SOLID-PHASE SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS AND OLIGONUCLEOTIDE SYNTHESIS METHOD NITTO DENKO CORPORATION (JP) 2013-11-28 US disclosed
EP-2666794-A1 Solid-phase support for oligonucleotide synthesis and oligonucleotide synthesis method Nitto Denko Corporation (JP) 2013-11-27 EP disclosed
EP-2298821-A1 Porous Resin Bead and Method for Producing Nucleic Acid Using the Same Nitto Denko Corporation (JP) 2011-03-23 EP disclosed
EP-2298820-A1 Porous Resin Bead and Method for Producing Nucleic Acid Using the Same Nitto Denko Corporation (JP) 2011-03-23 EP disclosed
US-20110065822-A1 POROUS RESIN BEAD AND METHOD FOR PRODUCING NUCLEIC ACID USING THE SAME NITTO DENKO CORPORATION (JP) 2011-03-17 US disclosed
US-20110065818-A1 POROUS RESIN BEAD AND METHOD FOR PRODUCING NUCLEIC ACID USING THE SAME NITTO DENKO CORPORATION (JP) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065822-A1 POROUS RESIN BEAD AND METHOD FOR PRODUCING NUCLEIC ACID USING THE SAME PCNA, PARN, PHAX L3MBTL1 3672/4885CNR2 3810/4885KCNH3 2852/4885
US-20110065818-A1 POROUS RESIN BEAD AND METHOD FOR PRODUCING NUCLEIC ACID USING THE SAME PCNA, ARID2, PARN L3MBTL1 3564/4885CNR2 3854/4885KCNH3 3254/4885
US-20150152234-A1 POROUS RESIN BEAD AND PRODUCTION METHOD OF NUCLEIC ACID BY USING SAME PCNA, ELL, NUP205 L3MBTL1 3907/4885CNR2 3898/4885KCNH3 3779/4885
US-20130317206-A1 SOLID-PHASE SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS AND OLIGONUCLEOTIDE SYNTHESIS METHOD PCNA, SSU72, POLR1G L3MBTL1 918/4885CNR2 4561/4885KCNH3 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.